RECURSION PHARMACEUTICALS, INC. Payments to Acquire Debt Securities, Available-for-sale
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Payments to Acquire Debt Securities, Available-for-sale of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2024-02-29
- RECURSION PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2021-12-31 was $116.97M.
- RECURSION PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2020-12-31 was $0.00.
- RECURSION PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $0.00.
- RECURSION PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- RECURSION PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2021 was $301.14M.
- RECURSION PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2020 was $0.00.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-29 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 | |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-08 | ||
| 2021-12-31 | $116.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $301.14M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $184.17M 10-Q · filed 2022-11-08 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $0.00 10-K · filed 2023-02-27 | |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-10 | ||
| 2019-12-31 | $0.00 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |